• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用索赔数据进行成本和成本效益研究。

Use of Claims Data for Cost and Cost-Effectiveness Research.

机构信息

Section of Cancer Economics and Policy, Department of Health Services Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

Division of Biostatistics, Washington University School of Medicine in St. Louis, MO.

出版信息

Semin Radiat Oncol. 2019 Oct;29(4):348-353. doi: 10.1016/j.semradonc.2019.05.009.

DOI:10.1016/j.semradonc.2019.05.009
PMID:31472737
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6719724/
Abstract

Administrative claims data are big data generated from healthcare encounters. Claims data contain information on insurance payment as well as clinical diagnoses and procedure codes to ascertain medical conditions and treatments, making them valuable sources for economic evaluation research. This paper offers an introductory overview of the use of claims data for oncology-related cost-of-illness, cost comparison, and cost-effectiveness analyses. We reviewed analytical methods commonly employed in these analyses, such as the phase of care approach and net costing method for cost-of-illness studies, propensity score matching methods for cost comparison studies, and net benefit regression models for cost-effectiveness studies. We used published studies to explain each method and to discuss methodological challenges of conducting economic studies using claims data.

摘要

行政索赔数据是从医疗保健中产生的大数据。索赔数据包含有关保险支付以及临床诊断和程序代码的信息,以确定医疗状况和治疗方法,这使得它们成为经济评估研究的有价值的来源。本文对索赔数据在癌症相关疾病成本、成本比较和成本效益分析中的应用进行了介绍性概述。我们审查了这些分析中常用的分析方法,如疾病成本研究中的治疗阶段方法和净成本法、成本比较研究中的倾向评分匹配方法以及成本效益研究中的净效益回归模型。我们使用已发表的研究来解释每种方法,并讨论使用索赔数据进行经济研究的方法学挑战。

相似文献

1
Use of Claims Data for Cost and Cost-Effectiveness Research.利用索赔数据进行成本和成本效益研究。
Semin Radiat Oncol. 2019 Oct;29(4):348-353. doi: 10.1016/j.semradonc.2019.05.009.
2
Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.估计结直肠癌患者护理发病成本方法的比较。
Med Care. 2009 Jul;47(7 Suppl 1):S56-63. doi: 10.1097/MLR.0b013e3181a4f482.
3
Administrative and claims records as sources of health care cost data.作为医疗保健成本数据来源的行政和理赔记录。
Med Care. 2009 Jul;47(7 Suppl 1):S51-5. doi: 10.1097/MLR.0b013e31819c95aa.
4
Actuarial analysis of private payer administrative claims data for women with endometriosis.对子宫内膜异位症女性私人付费者管理索赔数据的精算分析。
J Manag Care Pharm. 2007 Apr;13(3):262-72. doi: 10.18553/jmcp.2007.13.3.262.
5
Economic evaluation of alcoholism treatment.酒精中毒治疗的经济学评估。
Alcohol Res Health. 2006;29(1):27-33.
6
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source?癌症患者护理患病率成本估算方法的比较:数据源有何影响?
Med Care. 2009 Jul;47(7 Suppl 1):S64-9. doi: 10.1097/MLR.0b013e3181a23e25.
7
Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial.发展中国家多中心试验中的经济评估方法:来自世界卫生组织产前护理随机对照试验的案例研究
Paediatr Perinat Epidemiol. 1998 Oct;12 Suppl 2:75-97. doi: 10.1046/j.1365-3016.1998.00008.x.
8
The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and practice.医疗支出小组调查:一项支持医疗保健成本研究并为政策与实践提供信息的国家信息资源。
Med Care. 2009 Jul;47(7 Suppl 1):S44-50. doi: 10.1097/MLR.0b013e3181a23e3a.
9
Economic foundations of cost-effectiveness analysis.成本效益分析的经济基础。
J Health Econ. 1997 Feb;16(1):1-31. doi: 10.1016/s0167-6296(96)00506-1.
10
Health Care Resource Utilization and Costs for Influenza-like Illness Among Midwestern Health Plan Members.中西部健康计划成员中流感样疾病的医疗资源利用和成本。
J Manag Care Spec Pharm. 2015 Jul;21(7):568-73. doi: 10.18553/jmcp.2015.21.7.568.

引用本文的文献

1
Applications of artificial intelligence and the challenges in health technology assessment: a scoping review and framework with a focus on economic dimensions.人工智能的应用及卫生技术评估中的挑战:一项范围综述及聚焦经济维度的框架
Health Econ Rev. 2025 Jun 4;15(1):46. doi: 10.1186/s13561-025-00645-4.
2
Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims Analysis.杜氏肌营养不良症患者的磷酰二胺吗啉代寡聚物治疗模式评估:一项MarketScan索赔分析。
Adv Ther. 2025 Jan;42(1):523-536. doi: 10.1007/s12325-024-03044-z. Epub 2024 Nov 11.
3

本文引用的文献

1
Semiparametric Estimation of Longitudinal Medical Cost Trajectory.纵向医疗费用轨迹的半参数估计
J Am Stat Assoc. 2018;113(522):582-592. doi: 10.1080/01621459.2017.1361329. Epub 2018 Jun 18.
2
Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.评估针对一般风险女性的更新乳腺癌筛查指南的成本效益。
Value Health. 2019 Feb;22(2):185-193. doi: 10.1016/j.jval.2018.07.880. Epub 2018 Sep 8.
3
Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Between Scylla and Charybdis?-Health insurance claims-data to monitor quality of service delivery in ophthalmology.
在斯库拉和卡律布狄斯之间?——利用健康保险理赔数据监测眼科服务质量
Eye (Lond). 2024 Dec;38(18):3412-3415. doi: 10.1038/s41433-024-03333-5. Epub 2024 Sep 18.
4
Real-World Research on Retinal Diseases Using Health Claims Database: A Narrative Review.利用健康声明数据库对视网膜疾病进行的真实世界研究:一项叙述性综述。
Diagnostics (Basel). 2024 Jul 19;14(14):1568. doi: 10.3390/diagnostics14141568.
5
Multimorbidity healthcare expenditure in Belgium: a 4-year analysis (COMORB study).比利时多病种医疗支出研究:一项为期 4 年的分析(COMORB 研究)。
Health Res Policy Syst. 2024 Mar 22;22(1):35. doi: 10.1186/s12961-024-01113-x.
年轻男性前列腺癌调强放疗、质子放疗和立体定向体部放疗的毒性比较和成本。
J Clin Oncol. 2018 Jun 20;36(18):1823-1830. doi: 10.1200/JCO.2017.75.5371. Epub 2018 Mar 21.
4
Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis.基于回归的以患者为中心的成本效益分析方法。
Pharmacoeconomics. 2017 Jul;35(7):685-695. doi: 10.1007/s40273-017-0505-5.
5
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.《健康与医疗领域成本效益分析的实施、方法学实践和报告推荐:第二版》。
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
6
Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database.全国人口科学:来自台湾全民健康保险研究数据库的经验教训。
JAMA Intern Med. 2015 Sep;175(9):1527-9. doi: 10.1001/jamainternmed.2015.3540.
7
Considerations for observational research using large data sets in radiation oncology.放射肿瘤学中使用大型数据集进行观察性研究的注意事项。
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):11-24. doi: 10.1016/j.ijrobp.2014.05.013.
8
Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.SEER-Medicare 中肝细胞癌治疗方式的比较和成本效益分析。
Pharmacoeconomics. 2014 Jan;32(1):63-74. doi: 10.1007/s40273-013-0109-7.
9
A flexible model for the mean and variance functions, with application to medical cost data.一种用于均值和方差函数的灵活模型及其在医疗成本数据中的应用。
Stat Med. 2013 Oct 30;32(24):4306-18. doi: 10.1002/sim.5838. Epub 2013 May 13.
10
Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States.在过去 30 天的生命中使用放射疗法在美国的老年患者的大型基于人群的队列中。
J Clin Oncol. 2013 Jan 1;31(1):80-7. doi: 10.1200/JCO.2012.45.0585. Epub 2012 Nov 19.